Issue 104

Small Pharma’s CEO, George Tziras, on the commercialisation of psychedelic healthcare

It is a pivotal time for Small Pharma, as it anticipates data from its Phase IIa trial with lead candidate SPL026 – its proprietary DMT formulation.

As Small Pharma looks towards the latter stages of drug development, it has recalibrated its leadership accordingly, appointing George Tziras CEO in July.

Tziras, previously Chief Business Officer, has over 15 years’ experience in investment banking and capital markets, holding the position of Executive Director at Goldman Sachs before joining the company.

Since the appointment, Small Pharma has seen its share price surge 100%. PSYCH spoke with the new CEO on capital markets and the commercialisation of psychedelic healthcare.

ACT DECRIMINALISES PSYCHEDELIC MEDICINES

Up to two grams of psilocybin can be carried in Australian Capital Territory without criminal prosecution.

BECKLEY PSYTECH ACQUIRES ELEUSIS

As industry consolidation takes hold, UK-based Beckley Psytech has acquired former competitor Eleusis Therapeutics.

BUSINESS AND INVESTMENT

HMNC Brain Health raises additional €14.3m.

Patent strategies in psychedelic healthcare.

An overview of psychedelic healthcare.

NZ trial with ketamine for alcohol use disorder.

Algernon partners with Yale for Phase II DMT study.

Federally funded smoking cessation study with psilocybin.

SCIENCE AND RESEARCH

Mapping the brain’s neural response to psychedelic medicines.

Ketamine therapy compared with electroconvulsive therapy.

The mechanism of action behind psychedelic medicines.

Ketamine may reduce suicidal ideation in patients with depression.

emerging innovations in psychedelic healthcare

On Thursday, 17 November, healthcare leaders will converge in London to accelerate innovation in psychedelic medicine.

The event coincides with the release of The Psychedelics as Medicine Report: Fourth Edition, the industry’s leading data and insights publication, and Jefferies 2022 London Healthcare Conference.

To register your interest, please contact grace@psych.global

CONTACT FORM

REGULATION AND LEGISLATION

Accessing psychedelic healthcare in Canada.

Alberta’s emerging regulatory framework.

ARTICLES OF INTEREST

NHS gridlocked due to lack of community support.

Interaction between antihistamines and opioids.